Albemarle AI Stock Analysis
Albemarle (AMC) AI Stock Analysis
Albemarle
(BX Swiss:AMC)
No summary available
Albemarle Business Overview & Revenue Model
Company Description
Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts. The Lithium divi...
Albemarle Earnings Call Summary
The call was strongly positive overall. Albemarle reported substantial year-over-year growth in sales, adjusted EBITDA, margins, cash generation, energy-storage pricing, and specialties performance, while also achieving more than $150 million of productivity improvements and reducing capital expenditure guidance. Management highlighted strong lithium and stationary-storage demand, improving resource operations, and multiple growth opportunities. The principal challenges were lower lithium pricing and expected sequential declines in fourth-quarter energy-storage results, the earlier CGP3 outage, Middle East-related cost escalation, supply and contract uncertainty, and lithium-market volatility.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Albemarle raised its full-year specialties adjusted EBITDA outlook to $350 million-$375 million; expected full-year energy storage sales volumes remain in the range of 225,000-235,000 tons LCE, with fourth-quarter energy storage net sales and adjusted EBITDA expected to decrease sequentially, assuming today's lower market pricing persists for the remainder of the quarter, while volumes will be steady with the third quarter. For 2027, energy storage LCE sales volume is expected to be between 240,000 and 260,000 tons, with the full benefit of CGP3 and some other incremental production, while the more than $150 million in run rate cost and productivity improvements should translate into next year, though not all of it. Expected 2026 total capital expenditures were reduced to $300 million-$350 million from approximately $500 million, including less than $300 million of sustaining capital spending, and 2027 CapEx is expected to go up modestly, not a spike in CapEx spending.
Albemarle Risk Analysis
Albemarle disclosed 48 risk factors in its most recent earnings report. Albemarle reported the most risks in the "Production" category.
Latest Risks Added
0 New RisksAlbemarle Peers Comparison
Overall Rating
SQM69Neutral
EMN65Neutral
ESI62Neutral
ASH61Neutral
CC48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $15.15B | 11.28 | 23.63% | 4.48% | 58.56% | 189.59% | |
| 65Neutral | $7.61B | 11.66 | 10.63% | 5.12% | 0.40% | -6.58% | |
| 62Neutral | $8.26B | 39.53 | 7.39% | 0.96% | 39.62% | -14.83% | |
| Sector * | 61Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
| 61Neutral | $3.51B | 838.33 | 0.21% | 2.22% | 2.08% | ― | |
| 48Neutral | $2.07B | -12.13 | -117.69% | 2.62% | -0.51% | 49.73% |
* Basic Materials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ASH | Ashland Global Holdings, Inc. | 76.47 | 28.22 | 58.49% | |
| EMN | Eastman Chemical Company | 65.03 | 10.28 | 18.77% | |
| SQM | Sociedad Quimica Y Minera | 53.61 | -4.71 | -8.07% | |
| ESI | Element Solutions | 33.08 | 8.38 | 33.91% | |
| CC | Chemours Company | 13.29 | 2.20 | 19.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
